ArticleApplied microbiology and biotechnology2026
A broadly applicable split-luciferase biosensor approach for rapid antibody detection in emerging infectious diseases.
Article in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conventional immunoassays such as ELISA are widely used in serological testing, yet their reliance on multi-step workflows and labeled reagents limits diagnostic scalability and speed. Bioluminescence-based biosensors are attractive alternatives that offer high sensitivity, operational simplicity, and cost efficiency for detecting diverse analytes. Here, we present a broadly compatible bioluminescent biosensor for antibody detection based on analyte-mediated reconstitution of split-Nanoluciferase (NanoLuc). The platform utilizes engineered bifunctional probes, comprising the protein G C2 domain fused to split-NanoLuc subunits (LgBiT and SmBiT), which serve dual functions in antibody binding and signal generation. Upon immunocomplex formation with multi-epitope antigens, the probes colocalize LgBiT and SmBiT, reconstituting NanoLuc activity and producing a quantifiable bioluminescent signal. We implemented this Fc-binding split-NanoLuc complementation assay to detect antibodies against African swine fever virus (ASFV). The optimized system showed high sensitivity, a wide linear dynamic range, and no cross-reactivity with sera positive for other common swine viruses. Clinical validation exhibited 97.11% agreement with a commercial ELISA kit, confirming its practicality and reliability. Furthermore, the sensor platform was seamlessly adapted to detect antibodies against SARS-CoV-2 and Chikungunya virus (CHIKV) without requiring additional molecular design or reconfiguration, highlighting its inherent versatility. By leveraging the broadly applicable Fc-binding capacity of protein G and the intrinsic modularity of split-NanoLuc, this strategy streamlines assay development and eliminates the need for species-specific secondary antibodies. Together, our findings demonstrate a proof-of-concept biosensor approach that could be further developed into a useful tool for rapid antibody detection in emerging infectious disease settings. KEY POINTS: • Fungal biological processes alter upon illumination, also under the microscope • Red shifted fluorescent protein toolboxes decrease interference by illumination • Innovations like two-photon, lightsheet, and near IR microscopy reduce phototoxicity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.